The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that the first patient in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in combination with bevacizumab in advanced ovarian cancer has begun treatment.

MRD试验将评估这种治疗组合对微小残留病的影响。LAWRENCEVILLE，N.J.，2023年10月18日（GLOBE NEWSWIRE）-IMUNON，Inc。（纳斯达克股票代码：IMNN），一家专注于开发非病毒DNA介导的免疫疗法和下一代疫苗的临床阶段药物开发公司，宣布IMUNON的IMNN-001联合贝伐单抗治疗晚期卵巢癌的1/2期临床试验的第一位患者已开始治疗。

IMNN-001 is a DNA-based interleukin-12 (IL-12) immunotherapy currently in Phase 2 clinical development for the localized treatment of advanced ovarian cancer (the OVATION 2 Study). This Phase 1/2 trial is expected to enroll 50 patients with Stage III/IV advanced ovarian cancer. Patients undergoing frontline neoadjuvant therapy will be randomized 1:1 to receive standard chemotherapy plus bevacizumab vs.

IMNN-001是一种基于DNA的白细胞介素-12（IL-12）免疫疗法，目前正处于晚期卵巢癌局部治疗的2期临床开发阶段（OVATION 2研究）。该1/2期试验预计将招募50名III/IV期晚期卵巢癌患者。接受一线新辅助治疗的患者将随机1:1接受标准化疗加贝伐单抗vs。

chemotherapy plus bevacizumab and IMNN-001. The trial’s primary endpoint is detection of minimal residual disease (MRD) by second look laparoscopy (SLL) and the secondary endpoint is progression-free survival (PFS). Initial SLL data are expected within one year following the completion of enrollment and final PFS data are expected approximately three years following the completion of enrollment.

化疗加贝伐单抗和IMNN-001。该试验的主要终点是通过二次腹腔镜检查（SLL）检测微小残留病（MRD），次要终点是无进展生存期（PFS）。预计初始SLL数据将在注册完成后的一年内完成，最终PFS数据预计将在注册完成后约三年内完成。

This trial will also include a wealth of translational endpoints aimed at understanding the clonal evolution and immunogenomic features of the MRD phase of ovarian cancer that is currently undetectable by imaging or tumor markers. The principal investigator of this clinical trial is Amir Jazaeri, M.D., Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center.

该试验还将包括大量翻译终点，旨在了解目前无法通过成像或肿瘤标志物检测到的卵巢癌MRD期的克隆进化和免疫基因组学特征。该临床试验的主要研究者是德克萨斯大学MD安德森癌症中心的妇科肿瘤学和生殖医学教授Amir Jazaeri博士。

The Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Techn.

麻省理工学院科赫综合癌症研究所。